BrainsWay Ltd (BRSYF) posted $18.1 million in Q3 2026 revenue, doubled operating income to $2.6 million, and signaled full-year results at the high end of guidance on strong SWIFT and OCD demand.
Revenue increased 34% to $18.1 million in Q3 2026; Operating income rose 107% to $2.6 million and Adjusted EBITDA rose approximately 92% to $3.9 million Remaining performance obligations grew 31% year-over-year to approximately $85 million Shipped 130 Deep TMS systems in Q3 2026, a 44% increase year-over-year Full-year 2026 revenue, operating income margin and Adjusted EBITDA expected at the upper end of guidance with potential to modestly exceed it BURLINGTON, Mass. and JERUSALEM, Nov. 10, 2026
Detailed price information for Brainsway Ltd ADR (BWAY-Q) from The Globe and Mail including charting and trades.
Detailed price information for Brainsway Ltd ADR (BWAY-Q) from The Globe and Mail including charting and trades.
Detailed price information for Brainsway Ltd ADR (BWAY-Q) from The Globe and Mail including charting and trades.
Detailed price information for Cooper Companies (COO-Q) from The Globe and Mail including charting and trades.
On August 12, BrainsWay Ltd. (NASDAQ:BWAY) reported second-quarter 2026 results that make the neurostimulation company look less like a niche medtech story and more like a genuine growth compounder. Revenue climbed 35% year over year to a record $17.1 million, and adjusted EBITDA more than doubled to $3.5 million. The company shipped 125 Deep TMS […]
Investors need to pay close attention to BWAY stock based on the movements in the options market lately.
Detailed price information for Dyne Therapeutics Inc (DYN-Q) from The Globe and Mail including charting and trades.
The mean of analysts' price targets for Brainsway (BWAY) points to a 30.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Peer-reviewed secondary analysis adds to growing body of clinical evidence supporting the potential role of Deep TMS in addressing suicidal ideation among patients with major depressive disorderBURLINGTON, Mass. and JERUSALEM, Aug. 27, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the publication of new peer-reviewed data demonstrating significant reductions in suicid
This is the newest page. Registered accounts read further back.